Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661752 | 0.92 | DRD2 (0.55) | DRD2MCHR1KMT2AMEN1 | |
| SCHEMBL5659775 | 0.90 | DRD2 (0.60) | DRD2KMT2AMEN1CCR5 | |
| SCHEMBL5660458 | 0.88 | DRD2 (0.74) | DRD2 | |
| SCHEMBL6081736 | 0.87 | DRD2 (0.76) | DRD2MCHR1 | |
| SCHEMBL5661159 | 0.87 | DRD2 (0.63) | DRD2MCHR1KMT2AMEN1 | |
| SCHEMBL14619774 | 0.85 | DRD2 (0.60) | DRD2MCHR1 | |
| SCHEMBL5661751 | 0.84 | DRD2 (0.67) | DRD2MCHR1KMT2AMEN1 | |
| SCHEMBL5663252 | 0.84 | DRD2 (0.69) | DRD2MCHR1 | |
| SCHEMBL5661262 | 0.84 | DRD2 (0.66) | DRD2MCHR1SIGMAR1 | |
| SCHEMBL5663311 | 0.83 | DRD2 (0.64) | DRD2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | DRD2 119/4885LMNA 4566/4885MCHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.